Article

Study of mitoxantrone for the treatment of recurrent neuromyelitis Optica (Devic disease)

Harvard University, Cambridge, Massachusetts, United States
JAMA Neurology (Impact Factor: 7.01). 08/2006; 63(7):957-63. DOI: 10.1001/archneur.63.7.957
Source: PubMed

ABSTRACT Neuromyelitis optica is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. It is considered to have a B-cell-induced pathogenesis. Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, has been shown to primarily suppress the humoral response.
To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica.
Prospective 2-year study.
Academic multiple sclerosis center.
Five patients (3 women and 2 men) with an age range of 20 to 51 years and an Expanded Disability Status Scale score of 2.5 to 6.5 (mean +/- SD, 4.40 +/- 1.88).
Monthly intravenous infusions of mitoxantrone hydrochloride, 12 mg/m2, for 6 months followed by 3 additional treatments every 3 months.
Expanded Disability Status Scale score measured every 3 months and during relapses; findings on orbital, brain, and spinal cord magnetic resonance images performed at baseline and at 3, 6, 12, 18, and 24 months; and visual evoked potentials and results of ophthalmologic evaluations performed at baseline and annually.
During the 2 years of treatment, 2 patients each had a relapse once within the initial 5 months of treatment (1 severe and 1 moderate). Improvement was seen clinically and on magnetic resonance images in 4 patients. Patients generally tolerated the treatment well, although 1 patient had a reversible decrease in cardiac ejection fraction.
Our results suggest a beneficial effect of mitoxantrone treatment for relapsing neuromyelitis optica.

0 Followers
 · 
104 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: SUMMARY The chemotherapy agents like azathioprine and mitoxantrone (MITOX) are utilized in a routinely way in patients with multiple sclerosis. The azathioprine is used in the long-term treatment of myasthenia gravis (MG). The mitoxantrone is utilized for the management of the multiple sclerosis and the rituximab, a chimerical antibody monoclonal that exhausts the B cells, has been utilized in some autoimmune neurological diseases and its efficacy is now examining in various clinical trials. This review describes the benefits and secondary effects of the azathioprine, MITOX and rituximab. The azathioprine reduces the rate of relapses in the multiple sclerosis (EM) even in 21 percent, with a NNT of 7 to10 treatments to preventing a relapse in the first year; the rate of relapses in two years also diminishes. As the azathioprine has less secondary effects that the steroids, has been recommended like a "sparring steroids" in long-term management of the MG. Its adverse effects seem to be less prominent in the MG that in the EM because is utilized frequently in combination with steroids. The most common adverse effects are gastrointestinal and hematological (mielosupresion). An adverse but serious and rare effect is the major long-term risk of malignancy. The mitoxantrone was approved for the management of the progressive secondary multiple sclerosis, and in the crisis of relapses and remissions form. Various studies suggest that short-term modifies the course in the magnetic
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoantikörper gegen neuronale Strukturen gewinnen in der Differenzialdiagnostik und Klassifikation verschiedener neurologischer Erkrankungen zunehmend an Bedeutung, z. B. bei der Neuromyelitis optica, bei paraneoplastischen ZNS-Erkrankungen, beim Stiff-Person-Syndrom und bei Autoimmunepilepsien. Da es sich um seltene Syndrome handelt, liegen bislang keine ausreichend evidenzbasierten Therapiedaten vor. Zum aktuellen Zeitpunkt werden vorrangig verschiedene immunmodulatorische und -suppressive Substanzen angewendet, zusätzlich spielt bei paraneoplastischen Syndromen die Behandlung der zugrunde liegenden Krebserkrankung eine zentrale Rolle. Diese Übersicht dient der zusammenfassenden Darstellung der aktuellen Literatur hinsichtlich bisheriger Erfahrungen in der Behandlung und daraus abgeleiteten Therapieempfehlungen.
    Der Nervenarzt 04/2013; 84(4). DOI:10.1007/s00115-012-3608-4 · 0.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumen La concepción de que la neuromielitis óptica (NMO) es un trastorno inflamatorio monofásico, que afecta tanto a los nervios ópticos como a la medula espinal ha variado. En los últimos diez años, los resultados de varios estudios clínicos, radiológicos, serológicos y patológicos, han permitido modificar los axiomas de la NMO, una muestra de esto lo constituye su identificación como una entidad diferente de la Esclerosis Múltiple. Serológicamente se puede comprobar la presencia de un marcador tanto sensible como específico (IgG NMO), este anticuerpo se proyecta contra un antígeno, el aquaporina-4, el cual es el canal de agua más abundante del sistema nervioso, abriendo una nueva era en las investigaciones de los desórdenes desmielinizantes del sistema nervioso central. La posibilidad de determinar serológicamente este marcador, en pacientes con neuritis óptica o mielitis longitudinalmente extensa, y su capacidad de predecir las recaídas posteriores apoyan el concepto de espectro de tras-tornos de NMO. Se requieren nuevas investigaciones, que posibiliten nuevos conceptos patogénicos, además de estrategias terapéuticas eficaces que beneficien a los pacientes con esta patología. Palabras claves: neuromielitis óptica, neuromielitis, neuritis óptica, mielitis, aquaporina-4, enfermedad desmielinizante. Abstract The traditional view of neuromyelitis optica (NMO) is a monophasic inflammatory disorder that affects both the optic nerves and the spinal cord have been changing since last decated. Result from adecuated clinical trials, radiology, serologics and pathology investigations had modified the current nomenclature of demyelinating deseases leading identified NMO as a separate clinical entity from Multiple Sclerosis. The most abundant water channel in CNS aquaporin-4 has been identified as an specific target of IgG NMO specific autoantibody. This autoantibody could play an importan roll in pathogenesis of the Central nervous System Demyelinating Disorders. This features opens a new era to develop new serologic diagnostic and possible new terapeutical strategies. The identification of NMO-IgG in patients with recurrent optic neuritis or longitudinally extensive myelitis and its ability to predict subsequent relapse support the concept of a spectrum of NMO disorders. New clinical trials, and pathophysyiological investigations are required to hopefully lead to more effective targeted therapies for our patients and to improve our understan-ding about pathogenic mecanism underlaying in demielinization.